

Gender Affirming Care (GAC) - Maryland Prior Authorization Form

Please complete this <u>entire</u> form and fax it to 866-940-7328. If you have questions, please call 800-310-6826. This form may contain multiple pages. Please complete all pages to avoid a delay in our decision.

Allow at least 24 hours for review.

Incomplete Forms will not be reviewed.

Section A – Member Information							
First Name: Last Name:				Member ID:			
Address:							
City:	State:				ZIP Code:		
Phone:	e: DOB:				Allergies:		
Primary Insurance Information	(if any):						
Is the requested medication:	□ New or □	Continuation	of T	Therapy? If co	ntinuation,	list start o	late:
Is this patient currently hosp	italized? 🗆	Yes □ No If I	rece	ntly discharge	d, list disc	harge date):
Section B - Provider Information							
First Name:			Last Name:				
Address:			City:		State:	ZIP	code:
Phone:	Fax:	C:		:	Specialty:		
Office Contact Name / Fax atte	ntion to:						
Section C - Medical Information							
□ Trelstar® (triptorelin pamoate for injectable suspension □ Propecia tablets® (finasteride)			-	Diagnosis: Diagnosis Date:			
□ Other Strength:			Quantity:				
Directions:							
Section D – Previous Medication	Trials						
Medication Name	Strength	n Direction	ns	Dates of	Therapy		eason for iscontinuation
		_					
Section E – Additional Information	on						
	~						



Gender Affirming Care (GAC) - Maryland Prior Authorization Form

Member First Name:	Member Last Name:	Member DOB:					
Clinical and Drug Specific Information							
INITIAL AND REAUTHORIZATIONS							
_ , ,	cumentation of medical necessity for Gry care) or Mental Healthcare Profest der diverse population is required						
Healthcare Professional (e.g. primary	cumentation of medical necessity for G y care) or a Mental Health Professiona etencies in the assessment of transge	I who is a member of the					
☐ Treatment plan and clinical notes a	ttached to support request						
considered Discontinuation of all medications Height and weight will be monitore Renal function, liver function, lipids approval Testosterone levels will be monitore Individual will remain active in psychological lipids and und Laboratory Results (Reauthorization Testosterone levels attached (every	y 3 months within the first year, then ev	use of treatment, then every 6 months Il be monitored within 1 year of year then every 6 months thereafter of treatment ery 6 months)					
☐ Renal function, liver function, lipids, thereafter	, glucose, insulin, hemoglobin A1C with	in 1 year of approval and annually					
Authorization (Initial and Reauthorization): 12 months							
I certify that the benefits of the treatment for this patient outweigh the risks and verify that the information provided on this form is true and accurate to the best of my knowledge. UHC and prescriber acknowledge and agree that this request may be executed by electronic signature, which shall be considered as an original signature.							
Provider Signature:		Date:					

Confidentiality Notice: This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.